Dengue fever and international travel

Journal of Travel Medicine

Volumn 20, Issue 6, 2013, Pages 384-393

  Ratnam, Irani ^a,b   Leder, Karin ^a,c   Black, Jim ^b   Torresi, Joseph ^b,d  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d AUSTIN HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIVAX DENGUE; DENGUE VACCINE; DENV DENV CHIMERA; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; UNCLASSIFIED DRUG;

DENGUE; DENGUE VIRUS; HUMAN; INCIDENCE; INFECTION RISK; PUBLIC HEALTH PROBLEM; REVIEW; SEASONAL VARIATION; SERODIAGNOSIS; TRAVEL;

COMMUNICABLE DISEASES; DENGUE; DISEASE OUTBREAKS; HUMANS; TRAVEL; WORLD HEALTH;

EID: 84886950720     PISSN: 11951982     EISSN: 17088305     Source Type: Journal    
DOI: 10.1111/jtm.12052     Document Type: Review

References (92)

1. Kyle JL, Harris E,. Global spread and persistence of dengue. Annu Rev Microbiol 2008; 62: 71-92.
2. Meltzer E, Schwartz E,. A travel medicine view of dengue and dengue hemorrhagic fever. Travel Med Infect Dis 2009; 7: 278-283.
3. Bhatt S, Gething PW, Brady OJ,et al. The global distribution and burden of dengue. Nature 2013; 496: 504-507.
4. Wilder-Smith A, Schwartz E,. Dengue in travelers. N Engl J Med 2005; 353: 924-932.
5. Tantawichien T,. Dengue fever and dengue haemorrhagic fever in adolescents and adults. Paediatr Int Child Health 2012; 32 (Suppl 1): 22-27.
6. Gubler DJ,. Dengue and dengue hemorrhagic fever. Clin Microbiol Rev 1998; 11: 480-496.
7. Halstead SB, Lan NT, Myint TT, et al. Dengue hemorrhagic fever in infants: research opportunities ignored. Emerg Infect Dis 2002; 8: 1474-1479.
8. WHO-TDR. Dengue: guidelines for diagnosis, treatment, prevention and control. 2009. Available at http://whqlibdoc.who.int/publications/2009/ 9789241547871-eng.pdf. (Accessed 2012 Jul 19)
9. Cobelens FG, Groen J, Osterhaus AD, et al. Incidence and risk factors of probable dengue virus infection among Dutch travellers to Asia. Trop Med Int Health 2002; 7: 331-338.
10. Potasman I, Srugo I, Schwartz E,. Dengue seroconversion among Israeli travelers to tropical countries. Emerg Infect Dis 1999; 5: 824-827.
11. Baaten GG, Sonder GJ, Zaaijer HL, et al. Travel-related dengue virus infection, The Netherlands, 2006-2007. Emerg Infect Dis 2011; 17: 821-828.
12. Ratnam I, Black J, Leder K, et al. Incidence and seroprevalence of dengue virus infections in Australian travellers to Asia. Eur J Clin Microbiol Infect Dis 2012; 31: 1203-1210.
13. Morger H, Steffen R, Schar M,. Epidemiology of cholera in travellers, and conclusions for vaccination recommendations. Br Med J (Clin Res Ed) 1983; 286: 184-186.
14. Freedman DO, Weld LH, Kozarsky PE, et al. Spectrum of disease and relation to place of exposure among ill returned travelers. N Engl J Med 2006; 354: 119-130.
15. Burdino E, Milia MG, Sergi G, et al. Diagnosis of dengue fever in North West Italy in travelers from endemic areas: a retrospective study. J Clin Virol 2011; 51: 259-263.
16. Ansart S, Perez L, Vergely O, et al. Illnesses in travelers returning from the tropics: a prospective study of 622 patients. J Travel Med 2005; 12: 312-318.
17. Parola P, Soula G, Gazin P, et al. Fever in travelers returning from tropical areas: prospective observational study of 613 cases hospitalised in Marseilles, France, 1999-2003. Travel Med Infect Dis 2006; 4: 61-70.
18. O'Brien D, Tobin S, Brown GV, Torresi J,. Fever in returned travelers: review of hospital admissions for a 3-year period. Clin Infect Dis 2001; 33: 603-609.
19. Fenner L, Weber R, Steffen R, Schlagenhauf P,. Imported infectious disease and purpose of travel, Switzerland. Emerg Infect Dis 2007; 13: 217-222.
20. O'Brien DP, Leder K, Matchett E, et al. Illness in returned travelers and immigrants/refugees: the 6-year experience of two Australian infectious diseases units. J Travel Med 2006; 13: 145-152.
21. Allwinn R,. Significant increase in travel-associated dengue fever in Germany. Med Microbiol Immunol 2011; 200: 155-159.
22. Mohammed HP, Ramos MM, Rivera A, et al. Travel-associated dengue infections in the United States, 1996 to 2005. J Travel Med 2010; 17: 8-14.
23. McBride WJ, Mullner H, LaBrooy JT, Wronski I,. The 1993 dengue 2 epidemic in Charters Towers, North Queensland: clinical features and public health impact. Epidemiol Infect 1998; 121: 151-156.
24. Waterman SH, Novak RJ, Sather GE, et al. Dengue transmission in two Puerto Rican communities in 1982. Am J Trop Med Hyg 1985; 34: 625-632.
25. Kliks SC, Nimmanitya S, Nisalak A, Burke DS,. Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am J Trop Med Hyg 1988; 38: 411-419.
26. Allwinn R, Hofknecht N, Doerr HW,. Dengue in travellers is still underestimated. Intervirology 2008; 51: 96-100.
27. Janisch T, Preiser W, Berger A, et al. Emerging viral pathogens in long-term expatriates (II): Dengue virus. Trop Med Int Health 1997; 2: 934-940.
28. Sung V, O'Brien DP, Matchett E, et al. Dengue fever in travelers returning from southeast Asia. J Travel Med 2003; 10: 208-213.
29. Laferl H, Szell M, Bischof E, Wenisch C,. Imported dengue fever in Austria 1990-2005. Travel Med Infect Dis 2006; 4: 319-323.
30. Jelinek T, Muhlberger N, Harms G, et al. Epidemiology and clinical features of imported dengue fever in Europe: sentinel surveillance data from TropNetEurop. Clin Infect Dis 2002; 35: 1047-1052.
31. Streit JA, Yang M, Cavanaugh JE, Polgreen PM,. Upward trend in dengue incidence among hospitalized patients, United States. Emerg Infect Dis 2011; 17: 914-916.
32. Stienlauf S, Segal G, Sidi Y, et al. Epidemiology of travel-related hospitalization. J Travel Med 2005; 12: 136-141.
33. Wichmann O, Gascon J, Schunk M, et al. Severe dengue virus infection in travelers: risk factors and laboratory indicators. J Infect Dis 2007; 195: 1089-1096.
34. Lopez-Velez R, Perez-Casas C, Vorndam AV, et al. Dengue in Spanish travelers returning from the tropics. Eur J Clin Microbiol Infect Dis 1996; 15: 823-826.
35. Wichmann O, Hongsiriwon S, Bowonwatanuwong C, et al. Risk factors and clinical features associated with severe dengue infection in adults and children during the 2001 epidemic in Chonburi, Thailand. Trop Med Int Health 2004; 9: 1022-1029.
36. Anantapreecha S, Chanama S, An A, et al. Serological and virological features of dengue fever and dengue haemorrhagic fever in Thailand from 1999 to 2002. Epidemiol Infect 2005; 133: 503-507.
37. Sangkawibha N, Rojanasuphot S, Ahandrik S, et al. Risk factors in dengue shock syndrome: a prospective epidemiologic study in Rayong, Thailand. I. The 1980 outbreak. Am J Epidemiol 1984; 120: 653-669.
38. Wittesjo B, Eitrem R, Niklasson B,. Dengue fever among Swedish tourists. Scand J Infect Dis 1993; 25: 699-704.
39. Statler J, Mammen M, Lyons A, et al. Sonographic findings of healthy volunteers infected with dengue virus. J Clin Ultrasound 2008; 36: 413-417.
40. Meltzer E, Heyman Z, Bin H, Schwartz E,. Capillary leakage in travelers with dengue infection: implications for pathogenesis. Am J Trop Med Hyg 2012; 86: 536-539.
41. Schwartz E, Weld LH, Wilder-Smith A, et al. Seasonality, annual trends, and characteristics of dengue among ill returned travelers, 1997-2006. Emerg Infect Dis 2008; 14: 1081-1088.
42. Itoda I, Masuda G, Suganuma A, et al. Clinical features of 62 imported cases of dengue fever in Japan. Am J Trop Med Hyg 2006; 75: 470-474.
43. Wilder-Smith A, Tambyah PA,. Severe dengue virus infection in travelers. J Infect Dis 2007; 195: 1081-1083.
44. Jelinek T,. Dengue fever in international travelers. Clin Infect Dis 2000; 31: 144-147.
45. Jensenius M, Berild D, Ormaasen V, et al. Fatal subarachnoidal haemorrhage in a Norwegian traveller with dengue virus infection. Scand J Infect Dis 2007; 39: 272-274.
46. Lawn SD, Tilley R, Lloyd G, et al. Dengue hemorrhagic fever with fulminant hepatic failure in an immigrant returning to Bangladesh. Clin Infect Dis 2003; 37: e1-e4.
47. Jacobs MG, Brook MG, Weir WR, Bannister BA,. Dengue haemorrhagic fever: a risk of returning home. BMJ 1991; 302: 828-829.
48. Schmidt-Chanasit J, Tenner-Racz K, Poppert D, et al. Fatal dengue hemorrhagic fever imported into Germany. Infection 2011; 40: 441-443.
49. Sousa CA, Clairouin M, Seixas G, et al. Ongoing outbreak of dengue type 1 in the autonomous region of Madeira, Portugal: preliminary report. Euro Surveill 2012; 15-18.
50. Gjenero-Margan I, Aleraj B, Krajcar D, et al. Autochthonous dengue fever in Croatia, August-September 2010. Euro Surveill 2011; 2-5.
51. Gould EA, Gallian P, De Lamballerie X, Charrel RN,. First cases of autochthonous dengue fever and chikungunya fever in France: from bad dream to reality! Clin Microbiol Infect 2010; 16: 1702-1704.
52. Gill J, Stark LM, Clark GG,. Dengue surveillance in Florida, 1997-98. Emerg Infect Dis 2000; 6: 30-35.
53. Kuan MM, Lin T, Chuang JH, Wu HS,. Epidemiological trends and the effect of airport fever screening on prevention of domestic dengue fever outbreaks in Taiwan, 1998-2007. Int J Infect Dis 2010; 14: e693-e697.
54. Hanna JN, Richards AR, Esmonde JV, et al. Viraemic importations of dengue into north Queensland, 2009. Commun Dis Intell 2010; 34: 57-58.
55. Hunsperger EA, Yoksan S, Buchy P, et al. Evaluation of commercially available anti-dengue virus immunoglobulin M tests. Emerg Infect Dis 2009; 15: 436-440.
56. Schwartz E, Mileguir F, Grossman Z, Mendelson E,. Evaluation of ELISA-based sero-diagnosis of dengue fever in travelers. J Clin Virol 2000; 19: 169-173.
57. Guzman MG, Kouri G,. Dengue diagnosis, advances and challenges. Int J Infect Dis 2004; 8: 69-80.
58. Callahan JD, Wu SJ, Dion-Schultz A, et al. Development and evaluation of serotype- and group-specific fluorogenic reverse transcriptase PCR (TaqMan) assays for dengue virus. J Clin Microbiol 2001; 39: 4119-4124.
59. Wu SJ, Lee EM, Putvatana R, et al. Detection of dengue viral RNA using a nucleic acid sequence-based amplification assay. J Clin Microbiol 2001; 39: 2794-2798.
60. Houng HS, Chung-Ming Chen R, Vaughn DW, Kanesa-thasan N,. Development of a fluorogenic RT-PCR system for quantitative identification of dengue virus serotypes 1-4 using conserved and serotype-specific 3′ noncoding sequences. J Virol Methods 2001; 95: 19-32.
61. Fry SR, Meyer M, Semple MG, et al. The diagnostic sensitivity of dengue rapid test assays is significantly enhanced by using a combined antigen and antibody testing approach. PLoS Negl Trop Dis 2011; 5: e1199.
62. Hang VT, Nguyet NM, Trung DT, et al. Diagnostic accuracy of NS1 ELISA and lateral flow rapid tests for dengue sensitivity, specificity and relationship to viraemia and antibody responses. PLoS Negl Trop Dis 2009; 3: e360.
63. Lima Mda R, Nogueira RM, Schatzmayr HG, dos Santos FB,. Comparison of three commercially available dengue NS1 antigen capture assays for acute diagnosis of dengue in Brazil. PLoS Negl Trop Dis 2010; 4: e738.
64. Guzman MG, Jaenisch T, Gaczkowski R, et al. Multi-country evaluation of the sensitivity and specificity of two commercially-available NS1 ELISA assays for dengue diagnosis. PLoS Negl Trop Dis 2010; 4: e811.
65. Chaterji S, Allen JC Jr, Chow A, et al. Evaluation of the NS1 rapid test and the WHO dengue classification schemes for use as bedside diagnosis of acute dengue fever in adults. Am J Trop Med Hyg 2011; 84: 224-228.
66. Duong V, Ly S, Lorn Try P, et al. Clinical and virological factors influencing the performance of a NS1 antigen-capture assay and potential use as a marker of dengue disease severity. PLoS Negl Trop Dis 2011; 5: e1244.
67. Tricou V, Minh NN, Farrar J, et al. Kinetics of viremia and NS1 antigenemia are shaped by immune status and virus serotype in adults with dengue. PLoS Negl Trop Dis 2011; 5: e1309.
68. Huhtamo E, Hasu E, Uzcategui NY, et al. Early diagnosis of dengue in travelers: comparison of a novel real-time RT-PCR, NS1 antigen detection and serology. J Clin Virol 2010; 47: 49-53.
69. Watthanaworawit W, Turner P, Turner CL, et al. A prospective evaluation of diagnostic methodologies for the acute diagnosis of dengue virus infection on the Thailand-Myanmar border. Trans R Soc Trop Med Hyg 2011; 105: 32-37.
70. Fox A, Le NM, Simmons CP, et al. Immunological and viral determinants of dengue severity in hospitalized adults in Ha Noi, Viet Nam. PLoS Negl Trop Dis 2011; 5: e967.
71. Domingo C, de Ory F, Sanz JC, et al. Molecular and serologic markers of acute dengue infection in naive and flavivirus-vaccinated travelers. Diagn Microbiol Infect Dis 2009; 65: 42-48.
72. de Souza VA, Fernandes S, Araujo ES, et al. Use of an immunoglobulin G avidity test to discriminate between primary and secondary dengue virus infections. J Clin Microbiol 2004; 42: 1782-1784.
73. Matheus S, Deparis X, Labeau B, et al. Discrimination between primary and secondary dengue virus infection by an immunoglobulin G avidity test using a single acute-phase serum sample. J Clin Microbiol 2005; 43: 2793-2797.
74. Guy B, Barrere B, Malinowski C, et al. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine 2011; 29: 7229-7241.
75. Durbin AP, Kirkpatrick BD, Pierce KK, et al. Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine. Vaccine 2011; 29: 7242-7250.
76. Coller BA, Clements DE,. Dengue vaccines: progress and challenges. Curr Opin Immunol 2011; 23: 391-398.
77. Clements DE, Coller BA, Lieberman MM, et al. Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeys. Vaccine 2010; 28: 2705-2715.
78. Beckett CG, Tjaden J, Burgess T, et al. Evaluation of a prototype dengue-1 DNA vaccine in a Phase 1 clinical trial. Vaccine 2011; 29: 960-968.
79. Heinz FX, Stiasny K,. Flaviviruses and flavivirus vaccines. Vaccine 2012; 30: 4301-4306.
80. Sabchareon A, Wallace D, Sirivichayakul C, et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 2012; 380: 1559-1567.
81. Morrison D, Legg TJ, Billings CW, et al. A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults. J Infect Dis 2010; 201: 370-377.
82. Guy B, Saville M, Lang J,. Development of Sanofi Pasteur tetravalent dengue vaccine. Hum Vaccin 2010; 16: 6(9).
83. Guy B,. Immunogenicity of Sanofi Pasteur tetravalent dengue vaccine. J Clin Virol 2009; 46 (Suppl 2): S16-S19.
84. Guy B, Nougarede N, Begue S, et al. Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects. Vaccine 2008; 26: 5712-5721.
85. Barban V, Munoz-Jordan JL, Santiago GA, et al. Broad neutralization of wild-type dengue virus isolates following immunization in monkeys with a tetravalent dengue vaccine based on chimeric yellow fever 17D/dengue viruses. Virology 2012; 429: 91-98.
86. Lang J,. Recent progress on Sanofi Pasteur's dengue vaccine candidate. J Clin Virol 2009; 46 (Suppl 2): S20-S24.
87. Durbin AP, Karron RA, Sun W, et al. Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region. Am J Trop Med Hyg 2001; 65: 405-413.
88. Durbin AP, Whitehead SS, Shaffer D, et al. A single dose of the DENV-1 candidate vaccine rDEN1Delta30 is strongly immunogenic and induces resistance to a second dose in a randomized trial. PLoS Negl Trop Dis 2011; 5: e1267.
89. McArthur JH, Durbin AP, Marron JA, et al. Phase I clinical evaluation of rDEN4Delta30-200,201: a live attenuated dengue 4 vaccine candidate designed for decreased hepatotoxicity. Am J Trop Med Hyg 2008; 79: 678-684.
90. Thomas SJ, Endy TP,. Vaccines for the prevention of dengue: development update. Hum Vaccin 2011; 7: 674-684.
91. Lam SK, Burke D, Capeding MR, et al. Preparing for introduction of a dengue vaccine: recommendations from the 1st Dengue v2V Asia-Pacific Meeting. Vaccine 2011; 29: 9417-9422.
92. Chanthavanich P, Luxemburger C, Sirivichayakul C, et al. Short report: immune response and occurrence of dengue infection in Thai children three to eight years after vaccination with live attenuated tetravalent dengue vaccine. Am J Trop Med Hyg 2006; 75: 26-28.